Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

707944.pdf (935.79 KB)

Document type

Article

Version

Published version

Publication date

2020-09-01

Publication license

cc-by (c) Ramos Romero, Sara et al., 2020
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/175197

Modifications of gut microbiota after grape pomace supplementation in subjects at cardiometabolic risk: a randomized cross-over controlled clinical trial

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.3390/foods9091279

Abstract

Polyphenols are dietary bioactive compounds able to induce modifications in the gutmicrobiota profile, although more clinical studies are needed. With this aim, a randomized cross-overclinical trial was conducted, where 49 subjects at cardiometabolic risk (exhibiting at least two metabolicsyndrome factors) were supplemented with a daily dose of 8 g of grape pomace (GP) for 6 weeks,with an equivalent control (CTL) period. The levels of total bacteria and Bacteroidetes, Firmicutes,Lactobacilliales,BacteroidesandPrevotellawere estimated in fecal DNA by quantitative real-timePCR (qPCR), while fecal short-chain fatty acids (SCFAs) were assessed by gas chromatography.Several cardiometabolicmarkers were evaluated in blood samples. GP reduced insulin levels only inhalf of the participants (responders). GP supplementation did not cause significant modifications inthe microbiota profile of the whole group, except for a tendency (p=0.059) towards a decrease inthe proportion of Lactobacilliales, while it increased the proportion ofBacteroidesin non-respondersubjects. The reduction of insulin levels in subjects at cardiometabolic risk upon GP supplementationappears not to be induced by changes in the major subgroups of gut microbiota. Further studies at thespecies level may help to elucidate the possible role of microbiota in GP-induced insulinemic status

Subject

Microbiota intestinal, Malalties cardiovasculars

Subject (English)

Gastrointestinal microbiome, Cardiovascular diseases

Citation

Collections

Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
Articles publicats en revistes (Enginyeria Química i Química Analítica)

Citation

RAMOS ROMERO, Sara, et al. Modifications of gut microbiota after grape pomace supplementation in subjects at cardiometabolic risk: a randomized cross-over controlled clinical trial. Foods. 2020. Vol. 9, num. 9. ISSN 2304-8158. [consulted: 8 of August of 2026]. Available at: https://hdl.handle.net/2445/175197

Export metadata

JSON - METS

Share record